SHEDIR PHARMA GROUP S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.6 EUR | +2.27% |
|
-3.74% | -20.35% |
| Apr. 02 | Shedir Pharma, into 2023 with rising revenues; profit down single digits | AN |
| Mar. 29 | Shedir Pharma Group S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 63M 67.52M | Sales 2025 * | 67.7M 72.56M | Capitalization | 40M 42.87M |
|---|---|---|---|---|---|
| Net income 2024 * | 6M 6.43M | Net income 2025 * | 7M 7.5M | EV / Sales 2024 * | 0.41 x |
| Net cash position 2024 * | 14.3M 15.33M | Net cash position 2025 * | 23.1M 24.76M | EV / Sales 2025 * | 0.25 x |
| P/E ratio 2024 * |
5.97
x | P/E ratio 2025 * |
5.33
x | Employees | 79 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 12.01% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +2.27% | ||
| 1 week | -3.74% | ||
| Current month | -9.55% | ||
| 1 month | -5.26% | ||
| 3 months | -18.18% | ||
| 6 months | -20.70% | ||
| Current year | -20.35% |
1 week
3.34
3.72
1 month
3.344.00
Current year
3.344.68
1 year
3.345.10
3 years
2.705.22
5 years
2.708.80
10 years
2.708.80
| Managers | Title | Age | Since |
|---|---|---|---|
Antonio Scala
CEO | Chief Executive Officer | 39 | 13-12-31 |
Giuseppe Somma
IRC | Investor Relations Contact | - | 19-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marco Mazzarese
BRD | Director/Board Member | 45 | 18-12-31 |
Lucio Fusaro
BRD | Director/Board Member | 68 | 21-12-31 |
Umberto di Maio
FOU | Founder | 51 | 14-10-12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 3.6 | +2.27% | 7 250 |
| 24-04-24 | 3.52 | -3.30% | 19,500 |
| 24-04-23 | 3.64 | 0.00% | 0 |
| 24-04-22 | 3.64 | -0.55% | 2,000 |
| 24-04-19 | 3.66 | -2.14% | 250 |
Real-time Borsa Italiana, April 25, 2024 at 11:44 am EDT
More quotes
Shedir Pharma Srl is an Italy-based pharmaceutical company specialized in nutraceuticals, cosmetics and medical devices. The Company markets its products in different forms and under the brand lines Shedir Farmaceutici, Deimos Farmaceutici, Phobos Farmaceutici, Menkar Farmaceutici and Greenplanet Divisione Farmaceutica. Its products cover a wide range of therapeutics areas, such as cardiovascular, dermatology, neurology, urology, gynecology and dental health, among others.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.52
EUR
Average target price
8.08
EUR
Spread / Average Target
+129.55%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.35% | 42.74M | |
| +24.17% | 562B | |
| -6.62% | 358B | |
| +19.12% | 322B | |
| +8.06% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -11.64% | 149B | |
| -6.98% | 146B |
- Stock Market
- Equities
- SHE Stock
